|
OncoMinds Oncology Medical Communication Services
Overview of Cancer Indications
Various epidemiological surveys reiterated now and then about the rise in the global cancer prevalence rates due increase in life expectancy,
changing lifestyle and various other risk factors. Data says lung cancer is one of the most common types of cancer with approximately 1 million
new cases diagnosed each year but the fact is that in spite of newer advances in diagnosis and treatment five year survival rate for all lung
cancers combined is mere 15 %. This is the scenario among most of the cancers.
Incidence of colorectal cancer (CRC) is particularly high in western world and it is the second most common diagnosed cancer after lung cancer. It is estimated that in 2012 approximately 1.7 million people were affected by CRC. In spite of increase in the screening awareness the mortality
rates of CRC is increasing.
One of the most common diagnosed cancers apart of Lung cancer is Prostate cancer which is the second most common cause cancer related death in
men. Globally US has the highest incidence of prostate cancer.
In India Head and Neck Cancer is the most common cancer in men with high mortality rates. Most of the patients diagnosed only at the advanced
stages leading to the poor prognosis. Smoking and alcohol being found to be the most common risk factors attributed to the Head and Neck cancer.
Global Oncology Market
Report said that in 2009 global oncology market was estimated to be around $ 50 billion which is expected to reach approximately $ 75 billion by 2015.
Global cancer market is dominated by anti-neoplastics and cytostatic hormonal treatment. Among anti-neoplastics major focus is on the monoclonal antibodies (mAbs) which will be the key growth driver for the future.
Oncology has become the major focus areas for pharmaceutical and biotechnology companies due to the unmet needs in the treatment and diagnosis of various cancers. Reports say in 2009 around 16000 phase I, II and III trials listed on clinicaltrials.gov were cancer related with more evaluation of targeted therapies in different multiple cancers. It is presumed that targeted therapies are likely to be used in most cancers in the next 10-15 years.
Mediminds through its specilised Oncology services division - OncoMinds provides a one point complete solution of medical writing from clinical trial development to launch and post-launch scientific material.
| 
